Carla M Bann1, Richard T Abresch2, Barbara Biesecker2, Kristin Caspers Conway2, Chad Heatwole2, Holly Peay2, Peter Scal2, Jonathan Strober2, Karen Uzark2, Jodi Wolff2, Marjorie Margolis2, Angela Blackwell2, Natalie Street2, Angela Montesanti2, Julie Bolen2. 1. From RTI International (C.M.B.), Research Triangle Park, NC; University of California, Davis (R.T.A.); National Human Genome Research Institute (B.B.), Bethesda, MD; University of Iowa (K.C.C.), Iowa City; University of Rochester (C.H.), NY; Parent Project Muscular Dystrophy (H.P.), Hackensack, NJ; University of Minnesota (P.S.), Minneapolis; UCSF Benioff Children's Hospital (J.S.), San Francisco, CA; University of Michigan (K.U.), Ann Arbor; Muscular Dystrophy Association (J.W.), Chicago, IL; University of North Carolina (M.M.), Chapel Hill; RTI International (A.B.), Atlanta; and Centers for Disease Control and Prevention (N.S., A.M., J.B.), Atlanta, GA. cmb@rti.org. 2. From RTI International (C.M.B.), Research Triangle Park, NC; University of California, Davis (R.T.A.); National Human Genome Research Institute (B.B.), Bethesda, MD; University of Iowa (K.C.C.), Iowa City; University of Rochester (C.H.), NY; Parent Project Muscular Dystrophy (H.P.), Hackensack, NJ; University of Minnesota (P.S.), Minneapolis; UCSF Benioff Children's Hospital (J.S.), San Francisco, CA; University of Michigan (K.U.), Ann Arbor; Muscular Dystrophy Association (J.W.), Chicago, IL; University of North Carolina (M.M.), Chapel Hill; RTI International (A.B.), Atlanta; and Centers for Disease Control and Prevention (N.S., A.M., J.B.), Atlanta, GA.
Abstract
OBJECTIVES: The objectives of this study were to develop a conceptual model of quality of life (QOL) in muscular dystrophies (MDs) and review existing QOL measures for use in the MD population. METHODS: Our model for QOL among individuals with MD was developed based on a modified Delphi process, literature review, and input from patients and patient advocacy organizations. Scales that have been used to measure QOL among patients with MD were identified through a literature review and evaluated using the COSMIN (Consensus-Based Standards for the Selection of Health Measurement Instruments) checklist. RESULTS: The Comprehensive Model of QOL in MD (CMQM) captures 3 broad domains of QOL (physical, psychological, and social), includes factors influencing self-reported QOL (disease-related factors, support/resources, and expectations/aspirations), and places these concepts within the context of the life course. The literature review identified 15 QOL scales (9 adult and 6 pediatric) that have been applied to patients with MD. Very few studies reported reliability data, and none included data on responsiveness of the measures to change in disease progression, a necessary psychometric property for measures included in treatment and intervention studies. No scales captured all QOL domains identified in the CMQM model. CONCLUSIONS: Additional scale development research is needed to enhance assessment of QOL for individuals with MD. Item banking and computerized adaptive assessment would be particularly beneficial by allowing the scale to be tailored to each individual, thereby minimizing respondent burden.
OBJECTIVES: The objectives of this study were to develop a conceptual model of quality of life (QOL) in muscular dystrophies (MDs) and review existing QOL measures for use in the MD population. METHODS: Our model for QOL among individuals with MD was developed based on a modified Delphi process, literature review, and input from patients and patient advocacy organizations. Scales that have been used to measure QOL among patients with MD were identified through a literature review and evaluated using the COSMIN (Consensus-Based Standards for the Selection of Health Measurement Instruments) checklist. RESULTS: The Comprehensive Model of QOL in MD (CMQM) captures 3 broad domains of QOL (physical, psychological, and social), includes factors influencing self-reported QOL (disease-related factors, support/resources, and expectations/aspirations), and places these concepts within the context of the life course. The literature review identified 15 QOL scales (9 adult and 6 pediatric) that have been applied to patients with MD. Very few studies reported reliability data, and none included data on responsiveness of the measures to change in disease progression, a necessary psychometric property for measures included in treatment and intervention studies. No scales captured all QOL domains identified in the CMQM model. CONCLUSIONS: Additional scale development research is needed to enhance assessment of QOL for individuals with MD. Item banking and computerized adaptive assessment would be particularly beneficial by allowing the scale to be tailored to each individual, thereby minimizing respondent burden.
Authors: Michelle Eagle; Simon V Baudouin; Colin Chandler; David R Giddings; Robert Bullock; Kate Bushby Journal: Neuromuscul Disord Date: 2002-12 Impact factor: 4.296
Authors: David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays Journal: J Clin Epidemiol Date: 2010-08-04 Impact factor: 6.437
Authors: Craig M McDonald; Dawn A McDonald; Anita Bagley; Susan Sienko Thomas; Cathleen E Buckon; Eric Henricson; Alina Nicorici; Michael D Sussman Journal: J Child Neurol Date: 2010-06-17 Impact factor: 1.987
Authors: Philip A Powell; Jill Carlton; Donna Rowen; Fleur Chandler; Michela Guglieri; John E Brazier Journal: Neurology Date: 2021-03-30 Impact factor: 9.910